Abstract:11526 Background: Tumor necrosis rate after neoadjuvant therapy is one of the strongest predictors of long-term outcome for patients with osteosarcoma. Patients with good response (tumor necrosis rate ≥90%) have a substantially better survival than those with poor response (tumor necrosis rate < 90%), with 5-year overall survival of 75-80% and 55-65%, respectively. However, treatments for osteosarcoma have not yet shown much progress since the introduction of perioperative chemotherapy in 1970s. New neoadjuvant combinations are required to explored for osteosarcoma. Methods: In this phase II trial (NCT04294511), patients aged 14-65 years with histopathologically confirmed osteosarcoma and Eastern Cooperative Oncology Group performance status of 0-1 received three 21-day cycles of neoadjuvant regimen (camrelizumab 200 mg on day 1 of each cycle; doxorubicin 37.5 mg/m 2 or liposomal doxorubicin 25 mg/m 2 on days 1-2 of cycles 1 and 3; cisplatin 100 mg/m 2 on day 2 of cycles 1 and 3; methotrexate 8-12 g/m 2 on day 12 of cycle 1; and ifosfamide 3 g/m 2 on days 1-4 of cycle 2). Surgery was scheduled 12-14 days after neoadjuvant therapy. Two weeks after surgery, patients received 6 cycles of adjuvant therapy (camrelizumab 200 mg on day 1 of each cycle; doxorubicin 37.5 mg/m 2 or liposomal doxorubicin 25 mg/m 2 on days 9-10 of cycles 1, 3, and 5; cisplatin 100 mg/m 2 on day 10 of cycles 1, 3, and 5; methotrexate 8-12 g/m 2 on day 2 of cycles 1, 3, and 5; and ifosfamide 3 g/m 2 on days 1-4 of cycles 2, 4, and 6). The primary endpoint was good response (tumor necrosis rate ≥90%) rate after neoadjuvant therapy. Results: A total of 86 patients were screened and 75 patients signed informed consent from December 2019 to June 2022. By the data cutoff date on December, 2022, 8 patients did not complete neoadjuvant therapy and 2 patients refused surgery. 65 patients completed neoadjuvant therapy, one patient had disease progression before surgery, 64 received surgical resection and adjuvant therapy, and 44 completed adjuvant therapy. Thirty-one (48.4%, 95%CI: 36.6%-60.4%) of 64 patients showed good response. The most common grade 3-4 adverse events were decreased platelet count (44.0%), decreased white blood cell (37.3%), decreased neutrophil count (29.3%), oral mucositis (14.7%), increased alanine aminotransferase (12.0%), and increased aspartate aminotransferase (10.7%). Conclusions: Camrelizumab combined with doxorubicin, cisplatin, methotrexate and ifosfamide in the perioperative treatment of osteosarcoma patients were safe and tolerable. Postoperative good response rate was similar to previously reported results. Survival follow-up is still ongoing to analyze the effect of perioperative immunotherapy combined with chemotherapy on long-term outcomes of patients with osteosarcoma. Clinical trial information: NCT04294511 .

Clinical effects of deoxyribonucleotide natrium on leukocytopenia after new adjuvant chemotherapy for osteosarcoma

Doxorubicin Loaded Nano-Gel Preoperative Application Effect as Adjuvant Chemotherapy on Osteosarcoma

The assessment of the effectiveness of the adjuvant chemotherapy regimen for the treatment of osteosarcoma

Efficacy of Medroxyprogesterone Acetate Combined with Ondansetron on Preventing Vomiting Induced by Chemtherapy for Non-Small Cell Lung Cancer

[Enhancement effect of caffeine on chemotherapy of osteosarcoma in Fischer 344/N rats].

Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.

The Open, Multicenters, Double-Arms, Randomized, Parallel Controlled Clinical Trial of Lobaplatin or Gemcitabine Combined with Docetaxel As Second-Line Therapy for Advanced Osteosarcoma-the Effectiveness and Safety Analysis.

Changes And Significance Of Lymphocyte Subsets In Patients With Advanced Nsclc Before And After Endostar Combined Chemotherapy

[Efficacy and Safety Analysis of Different Dose Idarubicin Plus Cytarabine Regimen As Induction Chemotherapy for Young Patients with De-Novo Acute Myeloid Leukemia].

Sodium deoxyribonucleate effects on the status of cervical cancer patients after radiotherapy

Effect of Hypoxic Radiosensitizer Sodium Glycididazole on Long-Term Result of Radiotherapy for Nasopharyngeal Carcinoma

The Preliminary Report of a Randomized Controlled Multicenter Study of First-Line Chemotherapy Regimen Combined with Angiogenesis Inhibitor for Osteosarcoma of the Extremities

Antitumor Effects of Combining Doxorubicin Hydrochloride with Recombinant Human Endostatin in an Osteosarcoma Model

Arsenic trioxide inhibits the growth of Adriamycin resistant osteosarcoma cells through inducing apoptosis

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid

[Intradermal needling and acupuncture in prevention and treatment of leukopenia after chemotherapy with spleen-kidney deficiency: a randomized controlled trial]

Efficacy analysis of zoledronic acid combined with radiotherapy and combined with chemotherapy for bone metastasis of non-small cell lung cancer

Synergistic Antitumoral Efficacy of a Novel Replicative Adenovirus SG611-PDCD5 and Daunorubicin in Human Leukemic Cells

Efficacy and Safety of Ifosfamide-Based Chemotherapy for Osteosarcoma: A Meta-Analysis

A Meta-Analysis of the Efficacy and Safety of First-Line Chemotherapeutic Agents for Osteosarcoma.

Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate as neoadjuvant therapy for osteosarcoma: A single-arm, exploratory phase II trial.